GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nanosphere Health Sciences Inc (OTCPK:NSHSF) » Definitions » Debt-to-EBITDA

Nanosphere Health Sciences (Nanosphere Health Sciences) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Nanosphere Health Sciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nanosphere Health Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Nanosphere Health Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. Nanosphere Health Sciences's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.25 Mil. Nanosphere Health Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Nanosphere Health Sciences's Debt-to-EBITDA or its related term are showing as below:

NSHSF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.36
* Ranked among companies with meaningful Debt-to-EBITDA only.

Nanosphere Health Sciences Debt-to-EBITDA Historical Data

The historical data trend for Nanosphere Health Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanosphere Health Sciences Debt-to-EBITDA Chart

Nanosphere Health Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.05 -0.13 - - -

Nanosphere Health Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nanosphere Health Sciences's Debt-to-EBITDA

For the Biotechnology subindustry, Nanosphere Health Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanosphere Health Sciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nanosphere Health Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Nanosphere Health Sciences's Debt-to-EBITDA falls into.



Nanosphere Health Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Nanosphere Health Sciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.237
=0.00

Nanosphere Health Sciences's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.252
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Nanosphere Health Sciences  (OTCPK:NSHSF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Nanosphere Health Sciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Nanosphere Health Sciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanosphere Health Sciences (Nanosphere Health Sciences) Business Description

Traded in Other Exchanges
Address
1090 West Georgia Street, Suite 488, Vancouver, BC, CAN, V6E 3V7
Nanosphere Health Sciences Inc is a nano-biotechnology company. The company is focused on providing next-generation delivery of nutritive elements and medications. Its NanoSphere Delivery System platform technology addresses the problems of low bioavailability and excessive dosage amounts of a wide range of bioactive compounds. It focuses on developing nanoencapsulation technology for the delivery of nutritive elements and medicants through licensing arrangements.